Dr. Hatou presented recent research progress in 2020 ISSCR virtual conference.
Tokyo (JUNE 26, 2020)-, Dr. Hatou, founder & CEO of Cellusion Inc., presented recent research progress in 2020 International Society for Stem Cell Research (ISSCR) virtual annual conference held online from June 23rd to 27th. The title of the presentation is that Pilot Proof of Concept Study for Bullous Keratopathy Treatment by Corneal Endothelial Cells Substitute from Human iPS Cells with Monkey Model. With our cutting-edge cellular technology, Cellusion will accelerate our research program to deliver novel therapies for all bullous keratopathy patients.
Details on ISSCR, please see below.
<About Cellusion Inc.>
Cellusion Inc. is a regenerative medicine startup from Keio University. The mission of Cellusion is to deliver novel therapies for all Bullous Keratopathy patients by our iPS cells origin corneal endothelial cells mass culture system.
Company ： Cellusion Inc.
CEO ： Shin Hatou, M.D., Ph.D.
Headquarters ：1-13-7 Nihombashi-Muromachi, Chuo, Tokyo 103-0022, JAPAN
Founded ： January 2015